Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL).

Published

Journal Article

Histone H4 acetylation was examined by immunohistochemistry in patients with acute lymphocytic leukaemia (ALL) in first relapse. Univariate and multivariate models identified correlates of complete remission (CR) and overall survival (OS). No variables were associated with achievement of CR. In multivariate analysis, weak histone H4 acetylation [Hazard Ratio (HR) 2·20, 95% confidence interval (CI) 0·93-5·23, P=0·07], shorter interval from diagnosis to relapse (<9 vs. 9-24 vs. >24 months) (HR 1·82, 95% CI 1·20-2·75, P= 0·005), and central nervous system involvement (HR 3·43, 95% CI 1·31-8·99, P=0·01) were independent poor prognostic factors for OS. These data provide a rationale for the use of histone deacetylase inhibitors in the treatment of relapsed ALL.

Full Text

Duke Authors

Cited Authors

  • Advani, AS; Gibson, S; Douglas, E; Diacovo, J; Elson, P; Kalaycio, M; Copelan, E; Sekeres, M; Sobecks, R; Sungren, S; Lagoo, A; Rizzieri, D; Hsi, E

Published Date

  • May 2011

Published In

Volume / Issue

  • 153 / 4

Start / End Page

  • 504 - 507

PubMed ID

  • 21375525

Pubmed Central ID

  • 21375525

Electronic International Standard Serial Number (EISSN)

  • 1365-2141

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2141.2011.08607.x

Language

  • eng

Conference Location

  • England